Skip to content

Clinical study of pain relief oils in patients with osteoarthritis.

A parallel arm clinical study to evaluate the efficacy and safety of pain relief oils in patients with osteoarthritis - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/10/074997
Enrollment
60
Registered
2024-10-09
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M179- Osteoarthritis of knee, unspecified

Interventions

Intervention1: LS/PO/01: Apply a sufficient amount of oil on both knees with a gentle massage twice a day for 60 days. Intervention2: LS/PO/02: Apply a sufficient amount of oil on both knees with a ge

Sponsors

Life Synergy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Participants meeting all the following criteria will be eligible for the study: 1. Adults aged 45 to 65 years (both inclusive), of both sexes, with a Body Mass Index (BMI) not more than 30.00 kg per meter square; 2. Clinical diagnosis of osteoarthritis of the knee based on clinical evaluation and or radiographic evidence; 3. Participants with a pain visual analog scale (VAS) score between 1-7 (mild-moderate) preceding recruitment; 4. Participant ambulant and requiring treatment with an anti inflammatory drug and not receiving regular anti inflammatory or analgesic drugs or not satisfied with drugs being taken and seek a change; 5. Participants willing to come for regular follow up visits and provide data of the analgesic consumption during study period; 6. Participants can walk and give both verbal and written information regarding the study.

Exclusion criteria

Exclusion criteria: Participants meeting any of the following criteria will not be eligible for the study: 1. Participants incapacitated or bound to wheelchair or bed and unable to carry out self-care activities; 2. Treatment with intra-articular injection of corticosteroids into the knee within 3 months preceding study; 3. Ongoing treatment with anticoagulants, hydantoin, lithium, steroids, methotrexate, and colchicine; 4. Administration of intra-articular steroids in the past 3 months or hyaluronic acid in the last 9 months; 5. Indication of surgery for OA knee; 6. Arthroscopy of either knee in the past year; 7. Any condition that in the opinion of the investigator does not justify the participant’s inclusion for the study.

Design outcomes

Primary

MeasureTime frame
1. WOMAC A, B, and C subscale scores for pain, stiffness and physical disability. WOMAC-A is assessed by a Likert scale on a range from 0 (none) to 4 (extreme), with higher scores indicating higher levels of pain, WOMAC- B for levels of stiffness and WOMAC-C for levels of physical disability 2. VAS pain scale score 3. Knee range of motion (ROM) measured by goniometer 4. Symptom grading on a 4-point Linkert scale for joint swelling, tenderness, and warmthTimepoint: 1. Baseline, day 15, 30, day 60 2. Screening, baseline, day 15, 30, day 60 3. Screening and day 60 4. Baseline, day 15, 30, day 60

Secondary

MeasureTime frame
1. Adverse events profile 2. Tolerability of the investigational product Timepoint: From baseline to day 60.

Countries

India

Contacts

Public ContactDr Vaishnavi Patil

Life Synergy

vaishnavilifesynergy@gmail.com9834585994

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026